Microdosing GLP-1s for Wellness: Hidden Benefits & What Actually Works (2026 Update)

Описание: Are GLP-1 medications like Ozempic and Wegovy just weight-loss drugs? Not according to emerging 2026 research. I'm breaking down the hidden anti-inflammatory benefits of GLP-1s that most people don't know about—and the honest truth about whether microdosing for wellness actually works.

Take charge of your Health and become a patient:
http://shop.BespokeConciergeMD.com/

As a physician specializing in longevity medicine, I've dug deep into the science. Here's what we know (and what we don't):

What You'll Learn:
• Why GLP-1s reduce inflammation in just 3 weeks (with data from the SELECT trial)
• The 46% Alzheimer's risk reduction that shocked cardiologists
• How 20% cardiovascular protection happens WITHOUT weight loss
• Why microdosing for wellness is plausible but unproven
• The biomarkers you should track if you try GLP-1s
• The active clinical trial studying microdosed GLP-1s RIGHT NOW
• Who should consider GLP-1 therapy and who absolutely should not

00:00 Introduction: What Most People Get Wrong About GLP-1s: Not Just for Weight Loss
00:45 Is Microdosing GLP-1s the Key to Anti-Inflammatory Health?
02:02 GLP-1s and Inflammation: Medical Breakthroughs From the SELECT Study
03:34 4 Hidden GLP1 Benefits Beyond Weight Loss
05:31 Does Microdosing GLP-1s Work? Science vs. Hype Explained
07:16 How to Know If GLP-1 Microdosing Is Working: Biomarkers & Signs to Track
08:28 Are You a Candidate for Microdosing GLP-1s? Doctor’s Guide
10:06 Everything You Need to Know About GLP-1s for Wellness 2026 Update

#ozempic #longevitytips #wellness #metabolichealth #antiinflammatory #glp1medication #inflammation #doctoradvice

Clinical Trials & Studies Referenced:

*SELECT Trial (Semaglutide Cardiovascular Outcomes)*
Study: Semaglutide and Cardiovascular Outcomes in Patients With Obesity Without Diabetes
Details: 17,604 patients | 39.8-month follow-up | 20% reduction in MACE, 38% reduction in hsCRP at 104 weeks
Publication: New England Journal of Medicine (2024)
ClinicalTrials.gov: NCT03574597

*ELAD Trial (Liraglutide in Alzheimer's Disease)*
Study: Evaluating Liraglutide in Alzheimer's Disease (ELAD)
Details: 204 patients | 12-month treatment | 18% slower cognitive decline | 50% less brain volume loss
Publication: Alzheimer's & Dementia (2024)
ClinicalTrials.gov: NCT01843075

*Microdosed GLP-1 Wellness Trial (Ongoing)*
Study: Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures
Details: First systematic study of microdosing for wellness | Enrolling adults 18-65 | Started December 2024
ClinicalTrials.gov: NCT07092605

Disclaimer: This video is for informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Watching this video does not create a doctor-patient relationship. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have seen or heard in this video. Use of this information is at your own risk.

Visit our website to learn more.
http://www.BespokeConciergeMD.com